Abbott Laboratories Earnings

Abbott Laboratories’s revenue jumped 3.95% since last year same period to $10358Mn in the Q1 2025. On a quarterly growth basis, Abbott Laboratories has generated -5.61% fall in its revenue since last 3-months.

Abbott Laboratories’s net profit jumped 8.16% since last year same period to $1325Mn in the Q1 2025. On a quarterly growth basis, Abbott Laboratories has generated -85.64% fall in its net profits since last 3-months.

Abbott Laboratories’s net profit margin jumped 4.05% since last year same period to 12.79% in the Q1 2025. On a quarterly growth basis, Abbott Laboratories has generated -84.79% fall in its net profit margins since last 3-months.

Abbott Laboratories’s price-to-earnings ratio after this Q1 2025 earnings stands at 17.25.

Abbott Laboratories’s earning per share (EPS) estimates for the current quarter stand at 1.25 - a 16.82% jump from last quarter’s estimates.

Abbott Laboratories’s earning per share (EPS) estimates for the current year stand at 1.25.

Abbott Laboratories’s earning per share (EPS) jumped 11.22% since last year same period to 1.09 in the Q1 2025. This indicates that the Abbott Laboratories has generated 11.22% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Abbott Laboratories’s return on assets (ROA) stands at 0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Abbott Laboratories’s return on equity (ROE) stands at 0.31.

Abbott Laboratories declared 0.59 dividend per share during the earnings announcement for Q1 2025.